Novel formulations of dipyridamole with microenvironmental pH-modifiers for improved dissolution and bioavailability under hypochlorhydria

International Journal of Pharmaceutics

Volumn 434, Issue 1-2, 2012, Pages 148-154

  Taniguchi, Chika ^a,b   Inoue, Ryo ^a   Kawabata, Yohei ^a,b   Yamashita, Kazuhiro ^b   Wada, Koichi ^b   Yamauchi, Yukinori ^c   Yamada, Shizuo ^a   Onoue, Satomi ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^c MATSUYAMA UNIVERSITY   (Japan)

Author keywords

Bioavailability; Dipyridamole; Dissolution; Hypochlorhydric; pH modifier

Indexed keywords

DIPYRIDAMOLE; OMEPRAZOLE; TOLUENESULFONIC ACID; TOLUENESULFONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ACHLORHYDRIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROENVIRONMENT; NONHUMAN; PH; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACHLORHYDRIA; ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BENZENESULFONATES; BIOLOGICAL AVAILABILITY; DIPYRIDAMOLE; DISEASE MODELS, ANIMAL; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; MALE; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TIME FACTORS;

EID: 84864118263     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.05.040     Document Type: Article

References (18)

1. S.I. Badawy, and M.A. Hussain Microenvironmental pH modulation in solid dosage forms J. Pharm. Sci. 96 2007 948 959
2. J.M. Butler, and J.B. Dressman The developability classification system: application of biopharmaceutics concepts to formulation development J. Pharm. Sci. 99 2010 4940 4954
3. S. Chen, J. Zhu, F. Ma, Q. Fang, and Y. Li Preparation and characterization of solid dispersions of dipyridamole with a carrier copolyvidonum Plasdone S-630 Drug Dev. Ind. Pharm. 33 2007 888 899
4. K. Fukawa, K. Saitoh, O. Irino, K. Ohkubo, and S. Hashimoto Inhibitory mechanism of dipyridamole on platelet aggregation ex vivo Thromb. Res. 27 1982 333 340
5. L.A. Harker, and R.A. Kadatz Mechanism of action of dipyridamole Thromb. Res. Suppl. 4 1983 39 46
6. U. Heigoldt, F. Sommer, R. Daniels, and K.G. Wagner Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test Eur. J. Pharm. Biopharm. 76 2010 105 111
7. M.G. Issa, and H.G. Ferraz Intrinsic dissolution as a tool for evaluating drug solubility in accordance with the biopharmaceutics classification system Dissolut. Technol. 18 2011 6 13
8. E.S. Kostewicz, U. Brauns, R. Becker, and J.B. Dressman Forecasting the oral absorption behavior of poorly soluble weak bases using solubility and dissolution studies in biorelevant media Pharm. Res. 19 2002 345 349
9. G. Ricevuti, A. Mazzone, D. Pasotti, E. Uccelli, F. Pasquali, G. Gazzani, and G.B. Fregnan Pharmacokinetics of dipyridamole-beta-cyclodextrin complex in healthy volunteers after single and multiple doses Eur. J. Drug Metab. Pharmacokinet. 16 1991 197 201
10. T.L. Russell, R.R. Berardi, J.L. Barnett, T.L. O'Sullivan, J.G. Wagner, and J.B. Dressman pH-related changes in the absorption of dipyridamole in the elderly Pharm. Res. 11 1994 136 143
11. 2 Powder Technol. 196 2009 36 49
12. S. Siepe, B. Lueckel, A. Kramer, A. Ries, and R. Gurny Strategies for the design of hydrophilic matrix tablets with controlled microenvironmental pH Int. J. Pharm. 316 2006 14 20
13. S. Siepe, B. Lueckel, A. Kramer, A. Ries, and R. Gurny Assessment of tailor-made HPMC-based matrix minitablets comprising a weakly basic drug compound Drug Dev. Ind. Pharm. 34 2008 46 52
14. P.H. Stahl, and C.G. Wermuth Monographs on Acids and Bases 2011 Wiley-VCH Verlag GmbH & Co. Weinheim KGaA
15. I. Wada, M. Otaka, M. Jin, M. Odashima, K. Komatsu, N. Konishi, T. Matsuhashi, Y. Horikawa, R. Ohba, H. Itoh, and S. Watanabe Expression of HSP72 in the gastric mucosa is regulated by gastric acid in rats-correlation of HSP72 expression with mucosal protection Biochem. Biophys. Res. Commun. 349 2006 611 618
16. L.X. Yu, A.S. Carlin, G.L. Amidon, and A.S. Hussain Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs Int. J. Pharm. 270 2004 221 227
17. P. Zakeri-Milani, M. Barzegar-Jalali, M. Azimi, and H. Valizadeh Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability Eur. J. Pharm. Biopharm. 73 2009 102 106
18. R. Zhou, P. Moench, C. Heran, X. Lu, N. Mathias, T.N. Faria, D.A. Wall, M.A. Hussain, R.L. Smith, and D. Sun pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model Pharm. Res. 22 2005 188 192